Article
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
The Lancet. Oncology - 1 Feb 2013
Farley John, Brady William E, Vathipadiekal Vinod, Lankes Heather A, Coleman Robert, Morgan Mark A, Mannel Robert, Yamada S Diane, Mutch David, Rodgers William H, Birrer Michael, Gershenson David M
Abstract excerpt
BACKGROUND: Low-grade serous carcinoma of the ovary is chemoresistant but mutations in the MAPK pathway could be targeted to control tumour growth. We therefore assessed the safety and activity of selumetinib, an inhibitor of MEK1/2, for patients with this cancer. METHODS: In this open-label, single-arm phase 2 study, women (aged ≥18 years) with recurrent low-grade serous ovarian or peritoneal carcinoma were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.